Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.
about
Foxa2 and MafA regulate islet-specific glucose-6-phosphatase catalytic subunit-related protein gene expressionGlucose-6-phosphatase catalytic subunit gene familyMoving on from GWAS: functional studies on the G6PC2 gene implicated in the regulation of fasting blood glucose.Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of diseaseBanting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.Immunotherapy of type 1 diabetes: where are we and where should we be going?Coherent somatic mutation in autoimmune disease.Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice.The pathogenicity of self-antigen decreases at high levels of autoantigenicity: a computational approach.Fungal β-glucan, a Dectin-1 ligand, promotes protection from type 1 diabetes by inducing regulatory innate immune response.Stem cell treatment for type 1 diabetes.Mapping I-A(g7) restricted epitopes in murine G6PC2.Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice.An update on the use of NOD mice to study autoimmune (Type 1) diabetes.Prevention of "Humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approachIGRP and insulin vaccination induce CD8+ T cell-mediated autoimmune diabetes in the RIP-CD80GP mouse.Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets.Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseasesResponses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP.Deletion of the G6pc2 gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein does not affect the progression or incidence of type 1 diabetes in NOD/ShiLtJ miceNovel stable isotope analyses demonstrate significant rates of glucose cycling in mouse pancreatic islets.Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice.Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporinAntigen-specific therapeutic approaches in Type 1 diabetesAntigen targets of type 1 diabetes autoimmunityBeyond HLA-A*0201: new HLA-transgenic nonobese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+ T cell epitopes.The use of peptide-major-histocompatibility-complex multimers in type 1 diabetes mellitus.Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus.Antigen-specific induction of regulatory T cells for type 1 diabetes therapy.Constitutive and inflammatory immunopeptidome of pancreatic β-cells.B-cell cross-presentation of autologous antigen precipitates diabetes.T cell targeted immunotherapy for autoimmune disease.Identification of Candidate Tolerogenic CD8(+) T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model.Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes.Expression-Based Genome-Wide Association Study Links Vitamin D-Binding Protein With Autoantigenicity in Type 1 Diabetes.Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice.Efficient culture of CD8(+) T cells from the islets of NOD mice and their use for the study of autoreactive specificities.Multifunctional magnetic nanocarriers for image-tagged SiRNA delivery to intact pancreatic isletsDEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event
P2860
Q24653598-B7A932DF-F43B-4C4D-8209-8D1CEB187CD9Q28256072-0C94AB89-419F-4132-A5F2-DA7513D8EEF3Q33699177-29427AB4-59AD-451B-AE2A-2F6B6F09EF3FQ33729769-DB86B274-74D9-453C-82F9-7C7D2411AB03Q33750667-BB7CD782-875B-47FA-A2BB-76734853FC1CQ33815506-85D05356-0426-48BF-9E01-DD07ACC8303FQ33837769-84968000-EE8B-48E6-B5C2-511307111716Q33844333-727E03AD-78ED-4890-82A1-F0F996D400CAQ33941941-E9A7FC84-B554-4A0E-97A8-F2817FEEC164Q34219021-DE6B950A-A681-4D05-AC9C-6CEA6F4265CAQ34391021-AC982040-42EF-4CA7-A9E2-DBC22D7ED015Q34415712-43220709-C0B5-4011-9AF1-B0D3EC88C290Q34479316-FCEBC3AD-288F-428E-A5DE-C2E154A0D63DQ34508281-109D20E8-139B-4B6F-BEC7-55C532214D56Q34718795-4049652A-2C29-4622-8840-BE44B1E79904Q35081461-9DA1B836-0246-409B-86DD-FA1EC8C84C69Q35142798-361C272B-8F19-4C63-8ABB-57C792DC51EBQ35175394-A7A4DA3B-F138-488E-BAF2-AA8EEE82DF65Q35191064-7C95219F-CDA3-4CA4-A7E3-A56E0DE9C5C4Q35405027-FC717EEC-A4CB-49E8-A6F1-F5DE98B017B0Q35630803-0D175932-105B-4B44-90A6-AFF4FDB6E9AAQ35665104-1088B710-0386-45DD-9F7A-DC0755AAD9ADQ35751049-77B74B7C-F4B2-4272-AC61-E41C97931B48Q35762883-6602DA7B-A57E-42FD-AAF3-7CFC557D95A2Q35852999-A2BFD78A-EBF0-4F19-8F9F-57A742D61142Q35981325-25344BDA-07CE-495C-80A3-3D5D7F29E4C7Q36228996-3053BA61-6B9D-4B4D-B59E-DE0307D7F591Q36327358-9C7B2854-CB2D-4815-BEBC-C8DB6CDCD1F9Q36327362-7C78E5A8-382C-4F30-A784-38F4228D8CFDQ36339503-46503E0E-1EB8-4294-8298-001E59291611Q36339548-8056529A-38C5-4188-BFE6-7D095A014C5EQ36359571-22F4385B-7CFA-42EC-AABD-A6D4A33B4A43Q36741859-BA7CE08B-502C-44A8-9CB6-75E72C56DE31Q36755911-30DB6C67-8B3F-4AA0-9D91-65D83719FACCQ36820754-B02883F5-ED76-42AF-A2F6-787242584876Q36993836-F2424CDA-5037-443E-A8E7-4DE822A14F13Q37000552-65AB5D7F-E394-4E23-B6BB-82A4C238260DQ37182425-CB34A00B-3299-4647-ACA0-4DC792AE381EQ37249892-EC2A640C-4536-43CB-80DC-9AE843E33C70Q37389695-5B7ED027-1D14-4D9D-A704-B48F5A74EA9D
P2860
Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Prevention of diabetes by mani ...... ncy of a low-affinity peptide.
@en
type
label
Prevention of diabetes by mani ...... ncy of a low-affinity peptide.
@en
prefLabel
Prevention of diabetes by mani ...... ncy of a low-affinity peptide.
@en
P2093
P2860
P356
P1433
P1476
Prevention of diabetes by mani ...... ncy of a low-affinity peptide.
@en
P2093
Abdelaziz Amrani
Athanasius F M Marée
Bingye Han
Jun Yamanouchi
Pere Santamaria
P2860
P2888
P304
P356
10.1038/NM1250
P407
P577
2005-05-22T00:00:00Z
P5875
P6179
1036520217